Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity – No sedation or ataxia observed and treatment was well tolerated – Company plans to initiate a Phase 2...
Chimerix Provides Update on Research and Development Progress Highlights Advancement of Second Clinical Candidate, CMX16669, for CMV and BK Virus DURHAM, N.C., Oct. 16, 2014 (GLOBE NEWSWIRE) — Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing...
Relypsa Names Scott Garland Senior Vice President and Chief Commercial Officer REDWOOD CITY, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) — Relypsa, Inc. (Nasdaq:RLYP), today announced that Scott Garland has joined the company as senior vice president and chief...
Chimerix Names Two New Executives: Peter Payne as Senior Vice President, Business Development and Corporate Strategy, and Roberto Guzman, JD, MBA, MCLFS, as Vice President, Corporate Compliance DURHAM, N.C., Nov. 3, 2014 (GLOBE NEWSWIRE) — Chimerix, Inc....
Relypsa Announces Multiple Patiromer for Oral Suspension Abstracts to be Presented at American Society of Nephrology Annual Meeting 2014 Long-Term, Chronic Treatment Results Accepted for Late Breaking Poster Presentation REDWOOD CITY, Calif., Nov. 4, 2014 (GLOBE...
Awarepoint Names New CEO Nov 10, 2014 – Awarepoint Corporation, the largest real-time location system (RTLS) provider dedicated exclusively to healthcare, today announced the promotion of Tim Roche, formerly the company’s chief financial officer, to the position...
Recent Comments